請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67772
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 許聿翔(Yu-Hsiang Hsu) | |
dc.contributor.author | Che-Yu Lin | en |
dc.contributor.author | 林哲宇 | zh_TW |
dc.date.accessioned | 2021-06-17T01:48:59Z | - |
dc.date.available | 2022-08-20 | |
dc.date.copyright | 2020-09-22 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-17 | |
dc.identifier.citation | [1] J. A. DiMasi, L. Feldman, A. Seckler, and A. Wilson, 'Trends in risks associated with new drug development: success rates for investigational drugs,' Clin Pharmacol Ther, vol. 87, no. 3, pp. 272-7, 2010. [2] K. Smietana, M. Siatkowski, and M. Moller, 'Trends in clinical success rates,' Nat Rev Drug Discov, vol. 15, no. 6, pp. 379-80, 2016. [3] W. Mueller-Klieser, 'Multicellular spheroids,' Journal of cancer research and clinical oncology, vol. 113, no. 2, pp. 101-122, 1987. [4] R. Z. Lin and H. Y. Chang, 'Recent advances in three‐dimensional multicellular spheroid culture for biomedical research,' Biotechnology Journal: Healthcare Nutrition Technology, vol. 3, no. 9‐10, pp. 1172-1184, 2008. [5] F. Hirschhaeuser, H. Menne, C. Dittfeld, J. West, W. Mueller-Klieser, and L. A. Kunz-Schughart, 'Multicellular tumor spheroids: an underestimated tool is catching up again,' Journal of biotechnology, vol. 148, no. 1, pp. 3-15, 2010. [6] R. S. Kerbel, 'Tumor angiogenesis,' New England Journal of Medicine, vol. 358, no. 19, pp. 2039-2049, 2008. [7] E. Gottfried, L. A. Kunz-Schughart, R. Andreesen, and M. Kreutz, 'Brave little world: spheroids as an in vitro model to study tumor-immune-cell interactions,' Cell Cycle, vol. 5, no. 7, pp. 691-695, 2006. [8] P. Friedl and S. Alexander, 'Cancer invasion and the microenvironment: plasticity and reciprocity,' Cell, vol. 147, no. 5, pp. 992-1009, 2011. [9] W. J. Polacheck, A. E. German, A. Mammoto, D. E. Ingber, and R. D. Kamm, 'Mechanotransduction of fluid stresses governs 3D cell migration,' Proceedings of the National Academy of Sciences, vol. 111, no. 7, pp. 2447-2452, 2014. [10] K. Stock et al., 'Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery,' Sci Rep, vol. 6, p. 28951, 2016. [11] M. C. Cox, L. M. Reese, L. R. Bickford, and S. S. Verbridge, 'Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline,' ACS Biomaterials Science Engineering, vol. 1, no. 10, pp. 877-894, 2015. [12] M. E. Katt, A. L. Placone, A. D. Wong, Z. S. Xu, and P. C. Searson, 'In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform,' Front Bioeng Biotechnol, vol. 4, p. 12, 2016. [13] H.-F. Tsai, A. Trubelja, A. Q. Shen, and G. Bao, 'Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment,' Journal of The Royal Society Interface, vol. 14, no. 131, p. 20170137, 2017. [14] F. Hillen and A. W. Griffioen, 'Tumour vascularization: sprouting angiogenesis and beyond,' Cancer Metastasis Rev, vol. 26, no. 3-4, pp. 489-502, 2007. [15] S. A. Stacker, S. P. Williams, T. Karnezis, R. Shayan, S. B. Fox, and M. G. Achen, 'Lymphangiogenesis and lymphatic vessel remodelling in cancer,' Nat Rev Cancer, vol. 14, no. 3, pp. 159-72, 2014. [16] M. W. Tibbitt and K. S. Anseth, 'Hydrogels as extracellular matrix mimics for 3D cell culture,' Biotechnol Bioeng, vol. 103, no. 4, pp. 655-63, 2009. [17] W. Liu, J. C. Wang, and J. Wang, 'Controllable organization and high throughput production of recoverable 3D tumors using pneumatic microfluidics,' Lab Chip, vol. 15, no. 4, pp. 1195-204, 2015. [18] A. P. Aijian and R. L. Garrell, 'Digital microfluidics for automated hanging drop cell spheroid culture,' J Lab Autom, vol. 20, no. 3, pp. 283-95, 2015. [19] Y. C. Tung, A. Y. Hsiao, S. G. Allen, Y. S. Torisawa, M. Ho, and S. Takayama, 'High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array,' Analyst, vol. 136, no. 3, pp. 473-8, 2011. [20] A. Virgone-Carlotta et al., 'In-depth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil,' PLoS One, vol. 12, no. 11, p. e0188100, 2017. [21] P. Carmeliet, 'Mechanisms of angiogenesis and arteriogenesis,' Nature medicine, vol. 6, no. 4, pp. 389-395, 2000. [22] Y. Nashimoto et al., 'Integrating perfusable vascular networks with a three-dimensional tissue in a microfluidic device,' Integr Biol (Camb), vol. 9, no. 6, pp. 506-518, 2017. [23] Y. Nashimoto et al., 'Perfusable Vascular Network with a Tissue Model in a Microfluidic Device,' J Vis Exp, no. 134, 2018. [24] E. Sano, C. Mori, Y. Nashimoto, R. Yokokawa, H. Kotera, and Y. S. Torisawa, 'Engineering of vascularized 3D cell constructs to model cellular interactions through a vascular network,' Biomicrofluidics, vol. 12, no. 4, p. 042204, 2018. [25] S. Oh et al., ''Open-top' microfluidic device for in vitro three-dimensional capillary beds,' Lab Chip, vol. 17, no. 20, pp. 3405-3414, 2017. [26] J. Ko et al., 'Tumor spheroid-on-a-chip: a standardized microfluidic culture platform for investigating tumor angiogenesis,' Lab Chip, vol. 19, no. 17, pp. 2822-2833, 2019. [27] V. S. Shirure et al., 'Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids,' Lab Chip, vol. 18, no. 23, pp. 3687-3702, 2018. [28] H. Bruus, 'Acoustofluidics 1: Governing equations in microfluidics,' Lab Chip, vol. 11, no. 22, pp. 3742-51, 2011. [29] 楊文智, '腫瘤晶片之為流體平台開發,' 臺灣大學電機資訊學院生醫電子與資訊學研究所學位論文, pp. 16-100. [30] 吳東翰, '可應用於微組織之微流體系統開發-以質傳為基礎之生物反應器,' 臺灣大學應用力學研究所學位論文, pp. 16-97. [31] K. A. Materials, 'SU-8 2000 Data Sheet (2025-2075),' Available: http://web.mit.edu/3.042/team1_08f/documents/SU8-2050.pdf [32] Y. Xia and G. M. Whitesides, 'Soft lithography,' Annual review of materials science, vol. 28, no. 1, pp. 153-184, 1998. [33] L. Xiong, P. Chen, and Q. Zhou, 'Adhesion promotion between PDMS and glass by oxygen plasma pre-treatment,' Journal of Adhesion Science and Technology, vol. 28, no. 11, pp. 1046-1054, 2014. [34] C. Yang, W. Wang, and Z. Li, 'Optimization of corona-triggered PDMS-PDMS bonding method,' in 2009 4th IEEE International Conference on Nano/Micro Engineered and Molecular Systems, 2009: IEEE, pp. 319-322. [35] S. Johnson, H. Chen, and P.-K. Lo, 'In vitro tumorsphere formation assays,' Bio Protoc, vol. 3, no. 3, p. e325, 2013. [36] J. Folkman, 'Tumor angiogenesis: therapeutic implications,' New england journal of medicine, vol. 285, no. 21, pp. 1182-1186, 1971. [37] S. R. McDougall, A. R. Anderson, and M. A. Chaplain, 'Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies,' Journal of theoretical biology, vol. 241, no. 3, pp. 564-589, 2006. [38] Y.-H. Hsu, W.-W. Liu, T.-H. Wu, C. J.-T. Lee, Y.-H. Chen, and P.-C. Li, 'Study of diffusive-and convective-transport mediated microtumor growth in a controlled microchamber,' Biomedical Microdevices, vol. 21, no. 1, p. 7, 2019. [39] J. Folkman, 'Angiogenesis inhibitors generated by tumors,' Molecular medicine, vol. 1, no. 2, pp. 120-122, 1995. [40] J. Folkman, K. Watson, D. Ingber, and D. Hanahan, 'Induction of angiogenesis during the transition from hyperplasia to neoplasia,' Nature, vol. 339, no. 6219, pp. 58-61, 1989. [41] F. Rastinejad, P. J. Polverini, and N. P. Bouck, 'Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene,' Cell, vol. 56, no. 3, pp. 345-355, 1989. [42] D. J. Good et al., 'A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin,' Proceedings of the National Academy of Sciences, vol. 87, no. 17, pp. 6624-6628, 1990. [43] I. B. Lobov, P. C. Brooks, and R. A. Lang, 'Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo,' Proceedings of the National Academy of Sciences, vol. 99, no. 17, pp. 11205-11210, 2002. [44] L. J. McCawley and L. M. Matrisian, 'Matrix metalloproteinases: multifunctional contributors to tumor progression,' Molecular medicine today, vol. 6, no. 4, pp. 149-156, 2000. [45] M. Fang, J. Yuan, C. Peng, and Y. Li, 'Collagen as a double-edged sword in tumor progression,' Tumor Biology, vol. 35, no. 4, pp. 2871-2882, 2014. [46] A. Jabłońska-Trypuć, M. Matejczyk, and S. Rosochacki, 'Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs,' Journal of enzyme inhibition and medicinal chemistry, vol. 31, no. sup1, pp. 177-183, 2016. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67772 | - |
dc.description.abstract | 在本研究團隊之前的研究中,已開發出了以擴散質傳效應為主導的雙腔室三維微組織平台,一為以Vasculogenic血管新生術培養血管網絡的腔室,另一為培養腫瘤並用以誘導腫瘤血管新生的腔室,平台主要於低氧環境(5%O2)下進行培養,而因微組織平台由PDMS所組成,透過將PMDS的厚度控制在3-4mm厚且於微組織平台下方使用壓克力平板做為支撐的載台,可使微組織平台內部產生缺氧的環境。此外,給予平台內以寬度為50μm的連通孔互相連接的兩個腔室一穩定的靜水壓力,藉此控制提供的養分梯度以及腫瘤細胞及纖維母細胞釋放出血管新生因子(如VEGF)的濃度梯度,並透過測試不同培養參數培養出三維微組織。在此研究中,我們透過將腫瘤腔室的細胞通入口的設計進行改良,以順利地將平均直徑大小為763.55μm的結腸癌細胞球(SW480 tumor spheroid)和纖維母細胞(Fibroblast)混合纖維蛋白凝膠種入腫瘤腔室,但由於腫瘤細胞球結構與通道的限制,腫瘤細胞球的平均直徑在種入腔室後變成342.78μm,隨著培養至第14天,並在以擴散質傳的機制下,腫瘤細胞球逐漸增大,第14天的平均直徑達到615.71μm,若將細胞球視為一圓柱體,體積約增長3.2倍。透過缺乏養分及氧氣的三維腫瘤組織釋放出血管新生因子並產生穩定的濃度梯度,證實可以誘導血管腔室內已完成血管新生(Vasculogenesis process)的血管網絡產生血管新生芽(Angiogenic sprouts)並通過連通孔向腫瘤腔室進行生長。此外,根據腫瘤面積的大小,會影響血管網絡的平均面積比,且在腫瘤尺寸於培養14天後直徑為619.72μm時,可觀察到血管芽生進入腫瘤的現象,其中最大的腫瘤血管新生芽長度為1146.7μm,而最大的血管新生芽深度為1069.6μm,成功誘導腫瘤血管新生的現象。 透過此研究所開發的具有三維腫瘤組織的腫瘤晶片,期望在未來能建立更接近腫瘤於人體進行生長的微環境,以將其應用於疾病藥物的篩選過程,加速新藥的開發,並針對個人化醫療進行不同腫瘤細胞的研究,以此達到精準醫療的效用。 | zh_TW |
dc.description.abstract | In the previous study of our lab, a dual-chamber microfluidic platform that can develop three-dimensional microtissue using diffusive mass transports is developed. The vessel chamber is to develop a vascular network by using vasculogenic process, and the tumor chamber is to develop tumor and to induce tumor angiogenic process. The platform is cultured in 5%O2 incubator and the microchamber in the platform can create a hypoxic environment. In addition, the dual microtissue chambers connected by five 50μm micropores provide a constant hydrostatic pressure, controlling nutrient gradients and the concentration gradient of the vascular growth factors like VEGF released by SW480 cells and fibroblasts. In this study, the dual-chamber is redesign for loading a 763.55μm diameter of SW480 spheroid into the tumor chamber for the study of tumor angiogenic process. Using the diffusive mass transports, SW480 tumor spheroid can grow to an average diameter of 615.71μm after 14-day culture. In this environment, the tumor tissue lacks nutrients and oxygen, and it can start to releasese vascular growth factors generates a stable concentration gradient across the two chambers. The experimental studies verified that angiogenic sprouting can be induced and vessels can grow into the tumor chamber for tumor developed into 619.72μm diameter. The longest length of tumor angiogenesis is 1146.7μm, and the largest depth is 1069.6μm. These experiments verify that tumor angiogenesis can successfully induce by using the developed dual-chamber microfluidic platform. In summary, the present device provides a means to create a microenvironment closer to the microenviroment of tumors in the human body, that it potentially can be applied to the screening process of drugs for accelerating drug developing process. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:48:59Z (GMT). No. of bitstreams: 1 U0001-1408202020192000.pdf: 8034637 bytes, checksum: 47505ca51e9eda4c66a90aa8e7a7dba8 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書 i 致謝 ii 中文摘要 iii ABSTRACT iv 目錄 v 圖目錄 ix 表目錄 xii 第1章 緒論 1 1.1 前言 1 1.2 研究動機 2 1.3 研究目標 4 1.4 論文架構 5 第2章 文獻回顧 6 2.1 三維組織模型之培養技術 6 2.2 微流體平台之三維組織模型 7 2.2.1 血管新生機制 8 2.2.2 微流體平台之三維共培養組織模型與血管新生 8 2.2.3 微流體平台之三維腫瘤組織模型與血管新生 11 第3章 設計理念與研究方法 15 3.1 設計理念 15 3.1.1 微流體設計原理 16 3.1.2 可產生擴散質傳效應之三維微組織培養平台設計改良 22 3.2 有限元素法之微流體流場模擬分析 28 3.2.1 有限元素分析之建模 28 3.2.2 有限元素分析之統御方程式 29 3.2.3 有限元素分析之邊界條件 32 3.2.4 有限元素分析之材料屬性 33 3.2.5 有限元素分析之網格 34 第4章 平台開發與實驗方法 36 4.1 微流體平台系統之製程開發 36 4.1.1 微流體晶片製程 36 4.1.2 晶片光罩繪製與製作 37 4.1.3 黃光微影製程 38 4.1.4 微流道系統量測 48 4.1.5 微流道軟微影製程 48 4.1.6 微流體平台系統架設 52 4.2 細胞培養及生物技術 54 4.2.1 細胞培養技術 54 4.2.2 腫瘤細胞球培養液(Tumor spheroid medium)製作方法 55 4.2.3 腫瘤細胞球製作技術 58 4.2.4 細胞固定與免疫螢光染色 59 4.3 血管新生與腫瘤細胞球之量化分析 60 第5章 實驗結果與討論 62 5.1 微流體平台流場分析結果 62 5.1.1 擴散質傳效應之三維微組織培養平台流場 62 5.1.2 擴散質傳效應之三維微組織培養平台生長因子擴散分析 64 5.2 三維腫瘤組織之培養結果 67 5.3 三維腫瘤組織於擴散質傳效應之微流體平台培養結果 69 5.3.1 擴散質傳效應之三維微組織-腫瘤微組織 69 5.3.2 擴散質傳效應之三維微組織-腫瘤微血管 72 第6章 結論與未來展望 82 6.1 結論 82 6.2 未來展望 83 Reference 84 | |
dc.language.iso | zh-TW | |
dc.title | 可誘導腫瘤血管新生之微流體平台開發 | zh_TW |
dc.title | Development of a Microfluidic Device for the Induction of Tumor Angiogenesis | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 董奕鍾(Yi-Chung Tung),劉瑋文(Wei-Wen Liu) | |
dc.subject.keyword | 微流體,血管新生,腫瘤晶片,腫瘤細胞球,個人化醫療,藥物篩選, | zh_TW |
dc.subject.keyword | microfluidics,angiogenesis,tumor chips,tumor spheroid,personalized medicine,drug screening, | en |
dc.relation.page | 90 | |
dc.identifier.doi | 10.6342/NTU202003484 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-17 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 應用力學研究所 | zh_TW |
顯示於系所單位: | 應用力學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1408202020192000.pdf 目前未授權公開取用 | 7.85 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。